BHP Attracts AI-Focused Investors as Copper Demand Surges 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
NEW YORK, April 27, 2018 -- Kannalife Sciences, Inc. (“Kannalife”), a phyto-medical company, announced today that the Company’s CEO Dean Petkanas will be presenting at the 2018 Cannabinoids in Medicine Summit in Los Angeles on Saturday, April 28. Petkanas will be speaking on “Industry Advancements and New Frontiers – New Research Findings, Novel Drugs and Unique Delivery Systems” at 5:15pm PT.
The 2018 Cannabinoids in Medicine Summit brings together physicians, registered nurses and pharmacists engaged in the care of patients with various chronic diseases, allowing participants to learn from an elite group of experts about newer cannabinoid research and evidenced-based reviews examining the efficacy and safety of cannabinoids in critical therapeutic areas.
“At Kannalife we are always pleased to be called to participate at industry symposiums and conferences that focus on Cannabinoid therapeutics in the clinical setting.” Petkanas said “The Cannabinoid based therapeutics market is moving at a rapid pace, as seen by the recent 13-0 vote from the FDA’s advisory panel in favor of market approval for GW Pharmaceutical’s epilepsy drug EpidiolexTM. As for Kannalife, we are seeing great progress in the potential benefits of our own proprietary cannabidiol derived compound KLS-13019 in the treatment of disorders like Chemotherapy Induced Neuropathic Pain (CINP) and chronic diseases like Hepatic Enchephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE).”
About Kannalife Sciences
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
[email protected]
www.cmwmedia.com
